|Bid||9.89 x 1100|
|Ask||24.73 x 1400|
|Day's Range||20.56 - 25.19|
|52 Week Range||7.67 - 47.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for INBX
Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. Treatment was well tolerated, with no severe or serious adverse events related to the study drug. Related: Inhibrx Shares Interim Data On INBRX-106 - Keyt
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?